SVA Stock News 6.26 05/09/2014 19:19:04 Sinovac Biotech (SVA
Post# of 273249
Posted On: 05/09/2014 8:19:10 PM
Sinovac Biotech (SVA) 6.26 $SVA
Rotavirus Infections - Pipeline Review, H1 2014: 10 Companies and 10 Drugs Profiled
M2 - Thu May 08, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f34bxl/rotavirus) has announced the addition of the "Rotavirus Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rotavirus Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rotavirus Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rotavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rotavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved - Takeda Pharmaceutical Company Limited - Biological E. Limited - Medicago Inc. - Immuron Limited - Bharat Biotech International Limited - Shantha Biotechnics Limited - Sinovac Biotech Ltd. - Seek - Serum Institute of India Limited - Beijing Minhai Biotechnology Co., Ltd Drug Profiles - ORV-116E - IMM-272 - Rotavirus Vaccine - T-Cell Vaccine For Rotavirus - Rotavirus VLP Vaccine - Flagellin - Rotavirus Vaccine - Anti-HRV-3IgY - 5-Valent Rotavirus Vaccine - Monoclonal Antibody to Inhibit Nucleocapsid Protein for Rotavirus Infection For more information visit http://www.researchandmarkets.com/research/f34bxl/rotavirus
Global Influenza A Infections Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 41 Drug profiles
M2 - Tue Apr 29, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wjnvgk/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza A Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Influenza A Infections - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Vertex Pharmaceuticals Incorporated - Crucell N.V. - Hemispherx Biopharma, Inc. - Amarillo Biosciences, Inc. - SIGA Technologies, Inc. - Vironova AB - CureVac GmbH - PT Bio Farma - Viroblock S.A. - Innate Therapeutics Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Immune Targeting Systems (ITS) Ltd. - Sinovac Biotech Ltd. - Microbiotix, Inc. - Alios BioPharma, Inc. - ImmuneRegen BioSciences, Inc. - Vivaldi Biosciences Inc. - Humabs BioMed SA Drug Profiles - diridavumab - interferon alfa - FP-01 - CR-8020 - TCN-032 - midodrine hydrochloride - VX-787 - Avian Flu Vaccine - RG-7745 - Influenza A H7N7 vaccine - VIS-410 - Orvax - GSK-3206641-A - GSK-3206640A - H7N9 Vaccine - Homspera - rintatolimod - interferon alfa-n3 (human leukocyte derived) - Drug For Influenza A Infections - MIS-416 - Flufirvitide-3 - Nucleozin - Small Molecule For Influenza A - ET-001 - CR-8043 - FI-6 - Pam2Cys Vaccine For more information visit http://www.researchandmarkets.com/research/wj...nfluenza_a
Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV)
PR Newswire - Mon Apr 28, 5:09AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries. According to the agreement, Sinovac has committed to commercializing the vaccine in China, inclusive of conducting clinical trials, obtaining regulatory approval, and launching the sIPV vaccine. In addition, Sinovac has committed to having the capacity to supply, or making arrangements for the supply of, sIPV to the public sector of other countries in sufficient quantities to make a meaningful contribution to meeting global demand (e.g. at least 20 million doses annually).
Global Tetanus Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 29 Drug Profiles
M2 - Mon Apr 28, 2:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p5tm9w/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Panacea Biotec Limited - Bharat Biotech International Limited - Vaxin, Inc. - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - Act-HIB reconstituted with TRIPACEL - DTP-HepB-Polio-Hib - GC-1107 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - DTwP-HBV-Hib - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - Diphtheria Tetanus Pertussis Low Vaccine - Tetrabhay DTwP-H Vaccine - DTaP Vaccine - Adult Combinations TdaP Vaccine - TdaP Vaccine - Tetanus Vaccine - Diptheria And Tetanus Vaccine - Diptheria Tetanus And Pertussis Vaccine - DtwP-HB-Hib (liq) Vaccine - Tetanus Vaccine - GC-3111A - DTwP-IPV - LBVP-0101 - DTaP vaccine - Diphtheria Tetanus Acellular Pertussis Vaccine - Tetanus Vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib - DPT-H-HiB Vaccine For more information visit http://www.researchandmarkets.com/research/p5tm9w/tetanus
Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project
PR Newswire - Thu Apr 24, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading China-based vaccine manufacturer, announced today that it has received notification that a RMB 60 million free government grant has been approved by China's Ministry of Finance, National Development and Reform Commission, Ministry of Industry and Information Technology, and National Health and Family Planning Commission for construction of the Company's dedicated production facility for its Enterovirus 71 (EV71) vaccine against hand foot and mouth disease (HFMD). Given the severity of HFMD epidemic levels in China and the government's focus on developing the biotechnology industry, Sinovac's EV71 vaccine commercial production project was approved as one of the projects supported by the Dedicated Funds for Strategic New Emerging Industry Development. The funding criteria as outlined in this grant are to complete the construction of its production facility in compliance with China's new GMP guidelines with an annual capacity of 20 million doses of EV71 vaccine and to commercialize the vaccine in China. The grant will be funded in several tranches, of which RMB 20 million will be provided within the year, and the remaining will be provided after the criteria are met.
Pandemic Influenza - Pipeline Review, H1 2014 - Analysis of 33 Companies & 46 Drug Profiles
M2 - Wed Apr 23, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rtpnw/pandemic) has announced the addition of the "Pandemic Influenza - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Autoimmune Technologies, LLC - MedImmune, LLC - Emergent BioSolutions Inc. - Lentigen Corporation - Takeda Pharmaceutical Company Limited - Celltrion, Inc. - Novavax, Inc. - Vertex Pharmaceuticals Incorporated - Medicago Inc. - BioDiem Ltd - Adimmune Corporation - TechnoVax, Inc. - PDS Biotechnology Corporation - Theraclone Sciences, Inc. - Sinovac Biotech Ltd. - NanoBio Corporation - Protein Sciences Corporation - Immunovaccine, Inc. - VaxInnate Corporation - Immune Design Corp. - Sirnaomics, Inc. - VBI Vaccines - TSRL, Inc. - AltraVax Inc. - Big DNA Ltd. - PeptiVir, Inc. - Inhibikase Therapeutics, Inc. - Codagenix, Inc. - Medigen, Inc. For more information visit http://www.researchandmarkets.com/research/2rtpnw/pandemic
Sinovac Files 2013 Annual Report on Form 20-F
PR Newswire - Wed Apr 16, 8:15AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2013 on April 16, 2014. The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section.
Concise Analysis of the International Human Vaccine Industry
M2 - Tue Mar 25, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfnkh2/china_human) has announced the addition of the "Concise Analysis of the International Human Vaccine Industry" report to their offering. In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market. However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each. Key Topics Covered: 1. Overview of Vaccine Industry 2. Overview of China Human Vaccine Industry 3. Human Vaccine Market Segments in China 4. Human Vaccine Import and Export in China 5. Major Human Vaccine Producers in China Companies Mentioned: - Beijing Tiantan Biological Products Co., Ltd. - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd. - Dalian Hissen Bio-Pharm Co., Ltd. - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd. - Sinovac Biotech Ltd. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hf...hina_human
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Sinovac Biotech Shares Up 17.4% Since SmarTrend's Buy Recommendation (SVA)
Comtex SmarTrend(R) - Fri Mar 21, 9:23AM CDT
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on March 4th, 2014 at $6.82. In approximately 2 weeks, Sinovac Biotech has returned 17.39% as of today's recent price of $8.00.
Sinovac Biotech (SVA) Soars: Stock Rises 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:39AM CDT
Sinovac Biotech Ltd. was a big mover last session, as its shares rose over 17% on the day.
Nasdaq stocks posting largest volume increases
AP - Thu Mar 20, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 4:15PM CDT
Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 higher, practically erasing almost all of yesterday's losses. As per the norm, we got initial weekly jobless claims data today,...
Rev Shark: An Odd Market Day
at The Street - Thu Mar 20, 3:49PM CDT
Not bad action, just ... peculiar.
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 20, 12:54PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 19, 5:00PM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December 31, 2013.
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 Unaudited Financial Results
PR Newswire - Wed Mar 12, 5:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014 EDT. The Company will host a conference call prior to the market opening on Thursday, March 20, 2014, at 8:00 a.m. EDT (Thursday, March 20, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac's EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
PR Newswire - Wed Feb 26, 4:01PM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 ("EV71"
vaccine have been published online in the February 27th issue of The New England Journal of Medicine ("NEJM" . The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease ("HFMD" , or herpangina, was 94.8% among infants and young children and an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac's vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities.
4 Stocks Under $10 in Breakout Territory
at The Street - Wed Feb 12, 5:30AM CST
These under-$10 stocks are within range of triggering breakout trades.
Sinovac Biotech Ltd submits CTA with the CFDA to commence human clinical trials of its H7N9 avian influenza vaccine
M2 - Thu Jan 30, 3:10AM CST
Biopharmaceutical company Sinovac Biotech Ltd (NasdaqGS:SVA) reported on Wednesday the submission of a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to begin human clinical trials of its vaccine against Avian influenza A(H7N9) virus.
Rotavirus Infections - Pipeline Review, H1 2014: 10 Companies and 10 Drugs Profiled
M2 - Thu May 08, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f34bxl/rotavirus) has announced the addition of the "Rotavirus Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rotavirus Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rotavirus Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rotavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rotavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved - Takeda Pharmaceutical Company Limited - Biological E. Limited - Medicago Inc. - Immuron Limited - Bharat Biotech International Limited - Shantha Biotechnics Limited - Sinovac Biotech Ltd. - Seek - Serum Institute of India Limited - Beijing Minhai Biotechnology Co., Ltd Drug Profiles - ORV-116E - IMM-272 - Rotavirus Vaccine - T-Cell Vaccine For Rotavirus - Rotavirus VLP Vaccine - Flagellin - Rotavirus Vaccine - Anti-HRV-3IgY - 5-Valent Rotavirus Vaccine - Monoclonal Antibody to Inhibit Nucleocapsid Protein for Rotavirus Infection For more information visit http://www.researchandmarkets.com/research/f34bxl/rotavirus
Global Influenza A Infections Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 41 Drug profiles
M2 - Tue Apr 29, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wjnvgk/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza A Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Influenza A Infections - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Vertex Pharmaceuticals Incorporated - Crucell N.V. - Hemispherx Biopharma, Inc. - Amarillo Biosciences, Inc. - SIGA Technologies, Inc. - Vironova AB - CureVac GmbH - PT Bio Farma - Viroblock S.A. - Innate Therapeutics Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Immune Targeting Systems (ITS) Ltd. - Sinovac Biotech Ltd. - Microbiotix, Inc. - Alios BioPharma, Inc. - ImmuneRegen BioSciences, Inc. - Vivaldi Biosciences Inc. - Humabs BioMed SA Drug Profiles - diridavumab - interferon alfa - FP-01 - CR-8020 - TCN-032 - midodrine hydrochloride - VX-787 - Avian Flu Vaccine - RG-7745 - Influenza A H7N7 vaccine - VIS-410 - Orvax - GSK-3206641-A - GSK-3206640A - H7N9 Vaccine - Homspera - rintatolimod - interferon alfa-n3 (human leukocyte derived) - Drug For Influenza A Infections - MIS-416 - Flufirvitide-3 - Nucleozin - Small Molecule For Influenza A - ET-001 - CR-8043 - FI-6 - Pam2Cys Vaccine For more information visit http://www.researchandmarkets.com/research/wj...nfluenza_a
Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV)
PR Newswire - Mon Apr 28, 5:09AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries. According to the agreement, Sinovac has committed to commercializing the vaccine in China, inclusive of conducting clinical trials, obtaining regulatory approval, and launching the sIPV vaccine. In addition, Sinovac has committed to having the capacity to supply, or making arrangements for the supply of, sIPV to the public sector of other countries in sufficient quantities to make a meaningful contribution to meeting global demand (e.g. at least 20 million doses annually).
Global Tetanus Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 29 Drug Profiles
M2 - Mon Apr 28, 2:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p5tm9w/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Panacea Biotec Limited - Bharat Biotech International Limited - Vaxin, Inc. - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - Act-HIB reconstituted with TRIPACEL - DTP-HepB-Polio-Hib - GC-1107 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - DTwP-HBV-Hib - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - Diphtheria Tetanus Pertussis Low Vaccine - Tetrabhay DTwP-H Vaccine - DTaP Vaccine - Adult Combinations TdaP Vaccine - TdaP Vaccine - Tetanus Vaccine - Diptheria And Tetanus Vaccine - Diptheria Tetanus And Pertussis Vaccine - DtwP-HB-Hib (liq) Vaccine - Tetanus Vaccine - GC-3111A - DTwP-IPV - LBVP-0101 - DTaP vaccine - Diphtheria Tetanus Acellular Pertussis Vaccine - Tetanus Vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib - DPT-H-HiB Vaccine For more information visit http://www.researchandmarkets.com/research/p5tm9w/tetanus
Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project
PR Newswire - Thu Apr 24, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading China-based vaccine manufacturer, announced today that it has received notification that a RMB 60 million free government grant has been approved by China's Ministry of Finance, National Development and Reform Commission, Ministry of Industry and Information Technology, and National Health and Family Planning Commission for construction of the Company's dedicated production facility for its Enterovirus 71 (EV71) vaccine against hand foot and mouth disease (HFMD). Given the severity of HFMD epidemic levels in China and the government's focus on developing the biotechnology industry, Sinovac's EV71 vaccine commercial production project was approved as one of the projects supported by the Dedicated Funds for Strategic New Emerging Industry Development. The funding criteria as outlined in this grant are to complete the construction of its production facility in compliance with China's new GMP guidelines with an annual capacity of 20 million doses of EV71 vaccine and to commercialize the vaccine in China. The grant will be funded in several tranches, of which RMB 20 million will be provided within the year, and the remaining will be provided after the criteria are met.
Pandemic Influenza - Pipeline Review, H1 2014 - Analysis of 33 Companies & 46 Drug Profiles
M2 - Wed Apr 23, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rtpnw/pandemic) has announced the addition of the "Pandemic Influenza - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Autoimmune Technologies, LLC - MedImmune, LLC - Emergent BioSolutions Inc. - Lentigen Corporation - Takeda Pharmaceutical Company Limited - Celltrion, Inc. - Novavax, Inc. - Vertex Pharmaceuticals Incorporated - Medicago Inc. - BioDiem Ltd - Adimmune Corporation - TechnoVax, Inc. - PDS Biotechnology Corporation - Theraclone Sciences, Inc. - Sinovac Biotech Ltd. - NanoBio Corporation - Protein Sciences Corporation - Immunovaccine, Inc. - VaxInnate Corporation - Immune Design Corp. - Sirnaomics, Inc. - VBI Vaccines - TSRL, Inc. - AltraVax Inc. - Big DNA Ltd. - PeptiVir, Inc. - Inhibikase Therapeutics, Inc. - Codagenix, Inc. - Medigen, Inc. For more information visit http://www.researchandmarkets.com/research/2rtpnw/pandemic
Sinovac Files 2013 Annual Report on Form 20-F
PR Newswire - Wed Apr 16, 8:15AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2013 on April 16, 2014. The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section.
Concise Analysis of the International Human Vaccine Industry
M2 - Tue Mar 25, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfnkh2/china_human) has announced the addition of the "Concise Analysis of the International Human Vaccine Industry" report to their offering. In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market. However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each. Key Topics Covered: 1. Overview of Vaccine Industry 2. Overview of China Human Vaccine Industry 3. Human Vaccine Market Segments in China 4. Human Vaccine Import and Export in China 5. Major Human Vaccine Producers in China Companies Mentioned: - Beijing Tiantan Biological Products Co., Ltd. - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd. - Dalian Hissen Bio-Pharm Co., Ltd. - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd. - Sinovac Biotech Ltd. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hf...hina_human
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Sinovac Biotech Shares Up 17.4% Since SmarTrend's Buy Recommendation (SVA)
Comtex SmarTrend(R) - Fri Mar 21, 9:23AM CDT
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on March 4th, 2014 at $6.82. In approximately 2 weeks, Sinovac Biotech has returned 17.39% as of today's recent price of $8.00.
Sinovac Biotech (SVA) Soars: Stock Rises 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:39AM CDT
Sinovac Biotech Ltd. was a big mover last session, as its shares rose over 17% on the day.
Nasdaq stocks posting largest volume increases
AP - Thu Mar 20, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 4:15PM CDT
Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 higher, practically erasing almost all of yesterday's losses. As per the norm, we got initial weekly jobless claims data today,...
Rev Shark: An Odd Market Day
at The Street - Thu Mar 20, 3:49PM CDT
Not bad action, just ... peculiar.
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 20, 12:54PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 19, 5:00PM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December 31, 2013.
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 Unaudited Financial Results
PR Newswire - Wed Mar 12, 5:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014 EDT. The Company will host a conference call prior to the market opening on Thursday, March 20, 2014, at 8:00 a.m. EDT (Thursday, March 20, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac's EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
PR Newswire - Wed Feb 26, 4:01PM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 ("EV71"
vaccine have been published online in the February 27th issue of The New England Journal of Medicine ("NEJM" . The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease ("HFMD" , or herpangina, was 94.8% among infants and young children and an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac's vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities. 4 Stocks Under $10 in Breakout Territory
at The Street - Wed Feb 12, 5:30AM CST
These under-$10 stocks are within range of triggering breakout trades.
Sinovac Biotech Ltd submits CTA with the CFDA to commence human clinical trials of its H7N9 avian influenza vaccine
M2 - Thu Jan 30, 3:10AM CST
Biopharmaceutical company Sinovac Biotech Ltd (NasdaqGS:SVA) reported on Wednesday the submission of a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to begin human clinical trials of its vaccine against Avian influenza A(H7N9) virus.
(0)
(0)Scroll down for more posts ▼